Summary of HR 2636: Making Insulin Affordable for All Children Act

Purpose and Intent

The Making Insulin Affordable for All Children Act (HR 2636) aims to ensure that all children with diabetes have access to affordable insulin. The bill addresses the rising costs of insulin, which can be a significant financial burden for families, particularly those with limited resources. By making insulin more affordable, the legislation seeks to improve health outcomes for children who rely on this essential medication.

Key Provisions

While the full text of the bill is not provided, the following key provisions are anticipated based on the bill's title and intent:

• Price Caps on Insulin: The bill may propose limits on the out-of-pocket costs for insulin for children, ensuring that no family pays more than a specified amount per month.

• Insurance Coverage Requirements: It could mandate that health insurance plans cover insulin without imposing high deductibles or co-pays, making it more accessible to families.

• Support for Low-Income Families: The legislation may include provisions for subsidies or assistance programs aimed at helping low-income families afford insulin.

• Transparency in Pricing: The bill may require pharmaceutical companies to disclose pricing information to promote transparency and competition in the insulin market.

Who Would Be Affected

• Children with Diabetes: The primary beneficiaries of this legislation would be children diagnosed with diabetes who require insulin for their treatment.

• Families: Families of children with diabetes would experience reduced financial strain due to lower insulin costs.

• Healthcare Providers: Providers may see improved health outcomes in their pediatric patients due to better access to necessary medications.

• Pharmaceutical Companies: The bill could impact how insulin is priced and sold, potentially affecting the revenue and pricing strategies of these companies.

Legislative Process and Timeline

• Introduced: The bill was introduced in the House on April 3, 2025.

• Committee Referrals: Upon introduction, HR 2636 was referred to the Committee on Energy and Commerce, as well as the Committees on Ways and Means and Education and Workforce. The Speaker will determine the period for consideration by these committees.

• Next Steps: The bill will undergo discussions and potential amendments within the committees before it can be brought to the floor for a vote.

Sponsors

The bill is sponsored by:
- Greg Landsman (Primary Sponsor)
- Christopher R. Deluzio (Cosponsor)
- Madeleine Dean (Cosponsor)
- Eleanor Holmes Norton (Cosponsor)
- Josh Gottheimer (Cosponsor)
- Bennie G. Thompson (Cosponsor)
- Morgan McGarvey (Cosponsor)

Conclusion

HR 2636 represents a significant effort to address the affordability of insulin for children, aiming to alleviate financial burdens on families and improve health outcomes for young patients with diabetes. The bill's progress through the legislative process will be closely monitored as it moves through committee discussions and potential amendments.